Last updated on May 2018

A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204)

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of two INCB050465 treatment regimens in participants diagnosed with relapsed or refractory marginal zone lymphoma (MZL) who are naive to or were previously treated with a Bruton's tyrosine kinase (BTK) inhibitor.

Clinical Study Identifier: NCT03144674

Find a site near you

Start Over

University of Miami, SCCC

Miami, FL United States
  Connect »

Advanced Pharma - Miami

Located in: Miami, FL USA
  Connect »